{"id":"infliximab-and-immunosuppressives","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (bacterial, viral, fungal)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Opportunistic infections (tuberculosis, PCP)"}]},"_chembl":{"chemblId":"CHEMBL1201581","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infliximab is a chimeric monoclonal antibody that binds TNF-α, a key pro-inflammatory cytokine, preventing its interaction with TNF receptors and thereby reducing inflammation. When combined with immunosuppressive agents (such as methotrexate or azathioprine), this regimen provides synergistic immune suppression, reducing both TNF-mediated and broader T-cell-driven inflammatory pathways. This combination approach is commonly used in pediatric inflammatory bowel disease and other severe autoimmune conditions.","oneSentence":"Infliximab blocks tumor necrosis factor-alpha (TNF-α) to suppress inflammatory immune responses, while co-administered immunosuppressives further reduce immune activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:43.354Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Severe autoimmune inflammatory conditions in children"}]},"trialDetails":[{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT05947669","phase":"PHASE3","title":"Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-08-22","conditions":"Colitis","enrollment":195},{"nctId":"NCT03371095","phase":"PHASE3","title":"Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-05-25","conditions":"Behcet's Disease, Vasculitis","enrollment":53},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT04272788","phase":"","title":"Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2017-01-24","conditions":"Crohn Disease","enrollment":32},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT03775824","phase":"","title":"Faecal Analyses in Rheumatoid Arthritis Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-08-01","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT03370601","phase":"NA","title":"Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2017-01-03","conditions":"Inflammatory Bowel Diseases","enrollment":9},{"nctId":"NCT00705484","phase":"","title":"European Safety Registry in Ulcerative Colitis (P04808)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-01","conditions":"Ulcerative Colitis","enrollment":2239},{"nctId":"NCT02356445","phase":"","title":"Use of Immunosuppressive Therapy for Sarcoidosis","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2014-11","conditions":"Sarcoidosis","enrollment":2000},{"nctId":"NCT00514982","phase":"PHASE2","title":"Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-08-07","conditions":"Hermanski-Pudlak Syndrome, Colitis, Cytokines","enrollment":""},{"nctId":"NCT00075075","phase":"PHASE1","title":"Infliximab to Treat Non-Infectious Scleritis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2003-12-23","conditions":"Scleritis","enrollment":5},{"nctId":"NCT03192878","phase":"","title":"Infliximab Biosimilar in Takayasu's Arteritis","status":"UNKNOWN","sponsor":"Ospedale San Raffaele","startDate":"2017-03-01","conditions":"Takayasu Arteritis","enrollment":30},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT01505855","phase":"PHASE4","title":"Efficacy Study of Pneumococcal Vaccination in Crohn's Disease","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2011-12","conditions":"Crohn's Disease","enrollment":197},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310},{"nctId":"NCT01752790","phase":"PHASE4","title":"Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease","status":"WITHDRAWN","sponsor":"University of Roma La Sapienza","startDate":"2012-12","conditions":"Pediatric Crohn's Disease","enrollment":""},{"nctId":"NCT00724529","phase":"","title":"Post Marketing Surveillance of Remicade","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-06","conditions":"Crohn's Disease, Ankylosing Spondylitis","enrollment":938},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00753103","phase":"PHASE2","title":"Anti-Cytokine Therapy for Vasculitis","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2003-01","conditions":"Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis","enrollment":37},{"nctId":"NCT00307593","phase":"NA","title":"RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2004-05","conditions":"Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IFX, IMMs, AZA, MTX"],"phase":"marketed","status":"active","brandName":"Infliximab and immunosuppressives","genericName":"Infliximab and immunosuppressives","companyName":"Children's Hospital of Fudan University","companyId":"children-s-hospital-of-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infliximab blocks tumor necrosis factor-alpha (TNF-α) to suppress inflammatory immune responses, while co-administered immunosuppressives further reduce immune activation. Used for Pediatric inflammatory bowel disease (Crohn's disease and ulcerative colitis), Severe autoimmune inflammatory conditions in children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}